Southern California-based clinical-stage biopharmaceutical company focused on novel treatments for brain and central nervous system diseases nominated for Breakthrough Medical Technology Achievement Award
LOS ANGELES, May 9, 2024 (Globe Newswire) — NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, is proud to exhibit at the 2024 International Conference. california investment forum (CIF) will be held from May 8th to 11th at the Anaheim Majestic Garden Hotel in Anaheim, California.
In recognition of NeOnc’s contributions to medical technology, CIF has nominated NeOnc for the prestigious Breakthrough Medical Technology Achievement Award, presented by Treasurer Ma.
The forum features groundbreaking companies from more than 15 countries, providing unparalleled access to a network of investors and partners dedicated to fostering innovative solutions. California State Treasurer Fiona Ma will open the event, highlighting leading companies across multiple sectors including biotechnology, AI, clean energy, and financial services.
CEO of NeoOnc, Dr. Thomas Chenwill speak on Friday, May 10th at 10:45 a.m. Pacific Time, along with Executive Chairman Amir Heshmatpour, CFO Keithly Garnett, and COO Patrick Walters. They introduce NeOnc’s patented intranasal delivery system. This is a technology designed to allow therapeutic agents to bypass the blood-brain barrier via the olfactory or trigeminal nerves, potentially increasing therapeutic efficacy and convenience for patients.
NeOnc’s intellectual property portfolio is secured under exclusive worldwide rights from the University of Southern California (USC), with 135 US and international patents issued and pending.
Dr. Chen, a respected professor of neurosurgery and a medical expert who won last year’s Best in Medicine Award from the National Health Council, explains how this technology could impact patient outcomes. I will explain in detail.
About California Investment Forum
The California Investment Forum is a premier event that brings together innovative companies for exposure and access to a network of potential investors and partners. For more information, visit californiainvestmentforum.org.
About NeOnc Technologies Holdings, Inc.
NeOnc is a privately held clinical-stage biopharmaceutical company revolutionizing drug delivery and treatment for brain and central nervous system diseases. The company’s product, NEO212, is in human clinical trials, and several other proprietary drugs are in development. To learn more about NeOnc and its pioneering technology, visit neonctech.com.
Important note regarding forward-looking statements
All statements other than statements of historical fact contained in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding our expectations, potential or anticipated future actions, business strategies, events or results of operations. This includes statements regarding our expectations and projections, future financial or business performance or condition, and forward-looking statements. Words such as “anticipated”, “anticipated”, “may”, “anticipated” and similar expressions. The achievement or success of any matter covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Actual results may differ materially from current expectations or implied results.
NeOnc Technologies Holding, Inc. (the “Company”) cautions that the statements and assumptions made in this news release are forward-looking statements and are not guarantees of future performance. Forward-looking statements are based on management’s estimates and opinions at the date the statements are made. The information contained herein is current only as of the date of this document. The Company and its management undertake no obligation to update, change or revise any forward-looking statements after the date of this news release, whether as a result of new information, future events or otherwise, except as necessary. , expressly disclaimed. By law.
NeOnc Company Contact:
Patrick Walters
chief operating officer
NeOnc Technologies Holdings, Inc.
Contact us by email
NeOnc Investor Information:
ron both
CMA Investor Information
Phone (949) 432-7566
Contact us by email
NeOnc Media and ESG Contact:
Tim Randall
CMA For media personnel
Phone (949) 432-7572
Contact us by email
